非酒精性脂肪性肝病与肠道菌群失调新观点

doi:10.3969/j.issn.1672-5069.2014.03.035

Abstract

Abstract: Non-alcoholic fatty liver diseases （NAFLD） has an increasing worldwide prevalence. A ‘two-hit’ mechanism has been accepted,however,its pathogenesis remains to be clarified. Recently,some new findings about gut microbiota in NAFLD have emerged. It might be involved in gut permeability,low-grade inflammation and immune inbalance,and it is believed that it modulates dietary choline metabolism,regulates bile acid metabolism and produces endogenous ethanol. All of these factors are molecular mechanisms by which the microbiota can induce NAFLD or has some roles in the process from NAFLD to overt non-alcoholic steatohepatitis. This review summarizes the main literature findings about the relationships between gut microbiota and NAFLD.

Key words: Non-alcoholic fatty liver diseases, Gut microbiota, Lipopolysaccharide

Sun Lu, Lu Xiaolan. Perspectives in gut microbiota in non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 333-335.

References

[1] Ley RE,Turnbaugh PJ,Klein S. Gordon microbial ecology: human gut microbes associated with obesity. Nature,2006,444 （7122）:1022-1023.
[2] Tilg H,Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis. Hepatology,2010,52（5）:1836-1846.
[3] Bhatia LS,Curzen NP,Calder PC et al. Non-alcoholic fatty liver disease:a new and important cardiovascular risk factor Eur Heart J,2012,33:1190-1200.
[4] Soderberg C,Stal P,Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology,2010,51:595-602.
[5] Backhed F,Ding H,Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA,2004,101:15718-15723.
[6] Drenick EJ,Fisler J,Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole,irrespective of protein-calorie malnutrition. Gastroenterology,1982,82:535-548.
[7] Cani PD,Amar J,Iglesias MA et al. Metabolic endotoxemia initiatesobesity and insulin resistance. Diabetes,2007,56:1761-1772.
[8] Saberi M,Woods NB,de Luca Cet al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab,2009,10:419-429.
[9] Backhed F,Ding H,Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA,2004,101:15718-15723
[10] Alisi A,Ceccarelli S,Panera N et al. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol,2012,2:132.
[11] Machado MV,Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol,2012,11:440-449.
[12] Harte AL,da Silva NF,Creely SJ et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm （Lond）,2010,7: 15.
[13] Fujimoto Y,Fukase K. Structures,synthesis,and human Nod1 stimulation of immunostimulatory bacterial peptidoglycan fragments in the environment. J Nat Prod,2011,74:518-525.
[14] Verdam FJ,Rensen SS,Driessen A et al. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol,2011,45:149-152.
[15] Miele L,Valenza V,La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49:1877-1887.
[16] Wigg AJ,Roberts-Thomson IC,Dymock RB et al. The role of small intestinal bacterial overgrowth,intestinal permeability,endotoxaemia,and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut,2001,48:206-211.
[17] Gabele E,Dostert K,Hofmann C et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol,2011,55:1391-1399.
[18] De Gottardi A,McCoy KD. Evaluation of the gut barrier to intestinal bacteria in non-alcoholic fatty liver disease. J Hepatol,2011,55:1181-1183.
[19] Wang Z,Klipfell E,Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature,2011,472:57-63.
[20] Spencer MD,Hamp TJ,Reid RW,et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology,2011,140:976-986.
[21] Corbin KD,Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol,2012,28:159-165.
[22] Yokota A,Fukiya S,Islam KB et al. Is bile acid a determinant of the gut microbiota on a high-fat diet Gut Microbes,2012,3: 455-459.
[23] Turnbaugh PJ. Microbiology:fat,bile and gut microbes. Nature, 2012,487:47-48.
[24] Dekaney CM,von Allmen DC,Garrison AP,et al. Bacterial-dependent up-regulation of intestinal bile acid binding protein and transport is FXR mediated following ileo-cecal resection. Surgery,2008,144:174-181.
[25] Trauner M,Claudel T,Fickert P et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis,2010,28:220-224.
[26] Thomas C,Gioiello A,Noriega L,et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab,2009,10: 167-177.
[27] Keitel V,Haussinger D. Perspective:TGR5 （Gpbar-1） in liver physiology and disease. Clin Res Hepatol Gastroenterol,2012,36:412-419.
[28] Tremaroli V,Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature,2012,489:242-249.
[29] Zhu L,Baker SS,Gill C,et al. Characterization of the gut microbiome in non-alcoholic steatohepatitis（NASH） patients:a connection between endogenous alcohol and NASH. Hepatology,2012,doi:10.1002/hep.26093 [Epub ahead of print].
[30] Volynets V,Kuper MA,Strahl S et al. Nutrition, intestinal permeability,and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease（NAFLD）. Dig Dis Sci,2012,57:1932-1941.
[31] Li Z,Yang S,Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology,2003,37:343-350.
[32] Ma X,Hua J,Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol,2008,49:821-830.
[33] Loguercio C,Federico A,Tuccillo C et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol,2005,39:540-543.
[34] Million M,Angelakis E,Paul M et al. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog,2012,53:100-108.
[35] Aller R, De Luis DA,Izaola O,et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver diseasepatients:a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci,2011,15:1090-1095.
[36] Delzenne NM,Cani PD,Neyrinck AM. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose:experimental data. J Nutr,2007,137（Suppl 11）:2547S-2551S.
[37] Compare D,Coccoli P,Rocco A,et al. Gut-liver axis: the impact of gut microbiota on non- alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis,2012,22:471-476.
[38] Daubioul CA,Horsmans Y,Lambert P,et al. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr, 2005,59:723-726.

Perspectives in gut microbiota in non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[2]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[3]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[4]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.
[5]	Li Xin, Wang Hongyan, Chi Cheng, et al. Protective effect of berberine on endotoxin-induced intercellular hyperpermeability in Caco-2 cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 34-37.
[6]	Xie Wenrui, He Xingxiang. Fecal microbiota transplantation in chronic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 651-653.
[7]	Chen Hongjie, Peng Jie. Faecal microbiota transplantation in chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 654-657.
[8]	Zhang Lei，Liu Chao. Fecal microbiota transplantation in primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 658-659.
[9]	Liu Lulu, Wang Bingyuan. Gastrointestinal microbiota in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 660-662.
[10]	Yu Hongyan, Di Fusheng. Endocrinologists should pay attention to the outcome of liver diseases in patients with diabetes and non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 267-270.
[11]	Deng Yilin, Yu Heguo, Shi Min, et al.. Effect of oridonin on hepatic cytokine levels in mice with LPS/D-Gal-induced acute liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 294-297.
[12]	Zhao Wenxia，Zhang Lihui.. Application of Chinese traditional medicine in the treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 132-134.
[13]	Zhu Chanyan,Qu Jichen,Cao Haixia,et al.. Incidence of metabolic syndrome and non-alcoholic fatty liver diseases in patients with different histological types of lung cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 288-291.
[14]	Zhong Bihui. Appropriate application of lipid-regulating agents in patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 143-146.
[15]	Yan Jinsong, Yuan Dan, Li Dongsheng. Risk factors of non-alcoholic fatty liver in patients with diabetes type two [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 212-213.